ESPERION THERAPEUTICS INC. - COMMON STOCK

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

04 Aug 2022 13:05:01 By Nasdaq GlobeNewswire

Esperion Reports Second Quarter 2022 Financial Results and Provides Company Update

02 Aug 2022 04:00:02 By Nasdaq GlobeNewswire

Esperion Announces Establishment of Scientific Advisory Board to Support Pipeline and Life Cycle Management

25 Jul 2022 12:00:00 By Nasdaq GlobeNewswire

Esperion to Report Second Quarter 2022 Financial Results August 2, 2022

12 Jul 2022 05:00:02 By Nasdaq GlobeNewswire

Real World Data Analysis Reveals Nearly Half of All Adults at High Risk for ASCVD and Eligible for a Statin Were Not On Any Statin

03 Jun 2022 09:30:00 By Nasdaq GlobeNewswire

Esperion to Participate in the 2022 Jefferies Global Healthcare Conference

02 Jun 2022 05:00:01 By Nasdaq GlobeNewswire

Esperion Announces the Appointment of J. Martin Carroll to its Board of Directors

01 Jun 2022 13:00:00 By Nasdaq GlobeNewswire

Esperion Announces Five Abstracts Accepted for Presentation at the National Lipid Association Scientific Sessions

31 May 2022 05:00:01 By Nasdaq GlobeNewswire

Esperion to Participate in Upcoming H.C. Wainwright Global Investment Conference

17 May 2022 05:00:02 By Nasdaq GlobeNewswire

Esperion Reports First Quarter 2022 Financial Results and Provides Company Update

03 May 2022 04:00:01 By Nasdaq GlobeNewswire